摘要
目的探讨肺癌患者血清中SiSo细胞表达的受体结合肿瘤抗原(RCAS1)水平并进行分析,为临床诊治提供依据。方法采用酶联免疫吸附试验(ELISA)分别检测90例肺癌患者、60例良性肺部疾病患者和102名健康体检者血清RCAS1水平,并进行比较分析。结果肺癌组血清RCAS1水平与良性肺疾病组和健康对照组比较差异有统计学意义(P<0.05);随病程进展肺癌患者RCAS1的阳性率逐步升高,肺癌Ⅲ、Ⅳ期患者RCAS1阳性率(82.8%、95.8%)明显高于Ⅰ、Ⅱ期患者(42.9%、56.5%)(P值均<0.05);有淋巴结转移的患者RCAS1阳性率(80.6%)明显高于未转移患者(44.4%)(P<0.05)。RCAS1诊断肺癌的敏感度为73.3%,特异性为96.9%,准确性为88.5%。结论 RCAS1对肺癌的辅助诊断有一定的临床价值,可以作为一项新的肺癌标志物应用。
Objective To analyze the level of receptor-binding cancer antigen expressed on SiSo cells （ RCAS1 ） in patients with lung cancer in order to provide basis for clinical diagnosis and treatment. Methods The serum levels of RCASI in 90 lung cancer patients ,60 benign lung disease patients and 102 healthy controls were determined by enzyme-linked immunosorbent assay（ELISA）. Results The serum RCAS1 level in lung cancer patients was significantly higher than that in benign lung disease patients and healthy controls（ P 〈 0.05 ）. The positive rate of RCAS1 in lung cancer was steadly related with the course progress. The RCAS1 positive rate in patients with the stage HI or IVof lung cancer（82.8% and 95.8% ） was higher than that in those with the stage I or 1I （42.9% and 56.5% ） （P 〈0.05）. The RCAS1 positive rate in lung cancer patients with metastasis （80.6%） was higher than that in those without metastasis （44.4%） （P 〈 0.05 ）. The diagnostic sensitivity, specificity and accuracy of RCAS1 were 73.3%, 96.9% and 88.5%, respectively. Conclusion RCAS1 has clinical value for the diagnosis of lung cancer, and it can be used as a new tumor marker of lung cancer.
出处
《实用肿瘤杂志》
CAS
2013年第5期499-501,共3页
Journal of Practical Oncology
关键词
肺肿瘤
肿瘤标记
生物学
诊断
SiSo细胞表达的受体结合肿瘤抗原
酶联免疫吸附测定
lung neoplasms
tumor markers, biological
diagnosis
receptor-binding cancer antigen expressed on SiSo cells
enzyme-linked immunosorbent assay
